NEW YORK, May 18 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX) announced today Nesli Basgoz, M.D., has been named to the Board
of Directors. Dr. Basgoz was elected to serve unanimously by board members
at the Company's regularly scheduled board of directors meeting held today
in New York.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
Howard Solomon, Chairman and CEO of Forest commented: "Dr. Basgoz is a
brilliant and dedicated physician and researcher, primarily in the field of
infectious disease. She has received significant academic appointments
early in her career at the Harvard Medical School and Massachusetts General
Hospital.
"Medical science is essentially the basis for all that we do and we
expect Dr. Basgoz's insights, experience and extraordinary intelligence to
be valuable as we go forward in developing and acquiring new product
opportunities."
Dr. Basgoz is currently a Physician in Medicine at Massachusetts
General Hospital and Associate Chief for Clinical Affairs in its Division
of Infectious Disease. She is also Director, Infectious Disease Outpatient
Services and Director, HIV Clinical Services. Dr Basgoz is also an
Associate Professor of Medicine at Harvard Medical School.
Dr. Basgoz holds a M.D. from Northwestern University in Chicago,
Illinois and is Board Certified in both Internal Medicine and a
subspecialty of Infections Disease.
About Forest Laboratories
Forest Laboratories (http://www.frx.com) is a US-based pharmaceutical
company dedicated to identifying, developing and delivering products that
make a positive difference in peoples' lives. Forest Laboratories' growing
product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated
for adults for the initial and maintenance treatment of major depressive
disorder and for generalized anxiety disorder; Namenda(R) (memantine HCl),
an N-methyl-D- aspartate (NMDA)-receptor antagonist indicated for the
treatment of moderate to severe Alzheimer's disease; Benicar(R)*
(olmesartan medoxomil), an angiotensin receptor blocker, and Benicar*
HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor
blocker and diuretic combination product, each indicated for the treatment
of hypertension; and Campral(R)* (acamprosate calcium), indicated in
combination with psychosocial support for the maintenance of abstinence
from alcohol in patients with alcohol dependence who are abstinent at
treatment initiation.
*Benicar is a registered trademark of Sankyo Pharma, Inc., and Campral
is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA,
Darmstadt, Germany.
Except for the historical information contained herein, this release
contains "forward-looking statements" within the meaning of the Private
Securities Reform Act of 1995. These statements involve a number of risks
and uncertainties, including the difficulty of predicting FDA approvals,
the acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in the Forest
Laboratories' SEC reports, including the Company's Annual Report on Form
10-K for the fiscal year ended March 31, 2005, and on form 10-Q for the
periods ended June 30 ,2005, September 30, 2005 and December 31, 2005.
SOURCE Forest Laboratories, Inc.
 back to top
Related links:
http://www.frx.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
CONTACT:
Charles E. Triano, Vice President - Investor
Relations of Forest Laboratories, Inc., +1-212-224-6714,
Charles.Triano@frx.com
|
